FilingReader Intelligence

Huadong Medicine wins FDA approvals for drug trial, generic

July 23, 2025 at 07:59 AM UTC•By FilingReader AI

Huadong Medicine received US FDA approval for clinical trials of HDM1002 for weight management, following earlier Chinese regulatory approval.

The company's abbreviated new drug application for generic Caspofungin Acetate for Injection was also approved by US regulators.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Announcement regarding the wholly-owned subsidiary's receipt of US FDA new drug clinical trial approvalJuly 23, 2025 at 08:00 AM UTC

Supplementary Source Documents

Announcement regarding the approval by the US FDA of caspofungin acetate for injection, a drug product from a wholly-owned subsidiaryJuly 23, 2025 at 08:00 AM UTC

Huadong Medicine

SZSE:000963•Shenzhen Stock Exchange

RSS feed for Huadong Medicine

News Alerts

Get instant email alerts when Huadong Medicine publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →